Alpha Tau Medical Ltd.(DRTS)Earnings, Financials & Key Ratios
DRTS•NASDAQ
$7.85
$691M mkt cap·Price updated May 7, 2026
AboutAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA-$41M-17.5%
- Net Income-$43M-34.3%
- EPS (Diluted)-0.53-17.8%
- ROE-61%-41.3%
- ROIC-46.53%-26.1%
- Debt/Equity0.18-11.0%
- Interest Coverage-100.93+3.7%
DRTS Key Insights
Alpha Tau Medical Ltd. (DRTS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 15.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DRTS Price & Volume
Alpha Tau Medical Ltd. (DRTS) stock price & volume — 10-year historical chart
Loading chart...
DRTS Growth Metrics
Alpha Tau Medical Ltd. (DRTS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.44%
Return on Capital
10 Years-25.5%
5 Years-25.83%
3 Years-18.74%
Last Year-48.72%
DRTS Recent Earnings
Alpha Tau Medical Ltd. (DRTS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 9, 2026EPS
$0.14
Est $0.13
-7.7%
Revenue
—
Est $63,000
Q4 2025
Nov 20, 2025EPS
$0.14
Est $0.12
-16.7%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.13
Est $0.12
-8.3%
Revenue
—
Q2 2025
May 19, 2025EPS
$0.12
Est $0.14
+14.3%
Revenue
—
Est $25,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $0.14vs $0.13-7.7% | —vs $63,000 |
| Q4 2025 | Nov 20, 2025 | $0.14vs $0.12-16.7% | — |
| Q3 2025 | Aug 11, 2025 | $0.13vs $0.12-8.3% | — |
| Q2 2025 | May 19, 2025 | $0.12vs $0.14+14.3% | —vs $25,000 |
Based on last 12 quarters of dataView full earnings history →
DRTS Peer Comparison
Alpha Tau Medical Ltd. (DRTS) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 IART | 1.06B | 13.56 | -2.01 | 1.53% | -30.15% | -47.65% | 1.95 | |
 ARAY | 34.82M | 0.29 | -18.91 | 2.68% | -10.76% | -77.48% | 2.17 | |
 MRKR | 24.05M | 1.44 | -1.82 | -46.19% | -999999% | -289.66% | ||
 RLAY | 2.37B | 12.51 | -7.77 | 53.44% | -25.54% | -43.94% | 0.06 | |
 BLCO | 5.67B | 15.90 | -15.59 | 6.47% | -4.21% | -3.37% | 0.82 | |
 NVS | 277.42B | 145.39 | 20.22 | 5.97% | 24.14% | 31.42% | 0.80 | |
 MDT | 99.94B | 77.96 | 21.60 | 3.62% | 13% | 9.45% | 0.59 |
Compare DRTS vs Peers
Alpha Tau Medical Ltd. (DRTS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DRTS Income Statement
Alpha Tau Medical Ltd. (DRTS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | -86K▲ 0% | -776K▼ 802.3% | -979K▼ 26.2% | -1.07M▼ 9.7% | -1.1M▼ 2.6% | -1.23M▼ 11.8% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | -802.33% | -26.16% | -9.7% | -2.61% | -11.8% |
| Operating Expenses | 8.01M | 9.24M | 13.79M | 32.14M | 34.61M | 34.94M | 41.06M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.37M | 1.7M | 2.34M | 11.25M | 9.26M | 7.92M | 10.22M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 6.64M | 7.54M | 11.45M | 20.89M | 26.42M | 27.02M | 30.83M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -1.07M | 0 | 0 |
| Operating Income | -8.01M▲ 0% | -9.24M▼ 15.4% | -13.79M▼ 49.2% | -32.14M▼ 133.0% | 35.68M▲ 211.0% | -36.04M▼ 201.0% | -42.29M▼ 17.3% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -15.41% | -49.18% | -133.04% | 211.03% | -201.01% | -17.33% |
| EBITDA | -7.94M | -9.16M | -13.01M | -31.16M | 36.75M | -34.94M | -41.06M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -15.28% | -42.11% | -139.41% | 217.96% | -195.06% | -17.5% |
| D&A (Non-Cash Add-back) | 66K | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
| EBIT | -8.01M | -9.24M | -13.99M | -33.72M | -29.1M | -31.4M | -42.29M |
| Net Interest Income | 776K | 396K | -13.06M | 21K | 4.72M | 3.93M | 3.42M |
| Interest Income | 776K | 613K | 211K | 1.79M | 4.75M | 4.28M | 3.84M |
| Interest Expense | 0 | 217K | 13.27M | 1.77M | 39K | 344K | 419K |
| Other Income/Expense | -308K | 520K | -13.47M | -1.61M | 6.54M | 4.3M | -218K |
| Pretax Income | -8.32M▲ 0% | -8.72M▼ 4.9% | -27.26M▼ 212.5% | -33.74M▼ 23.8% | -29.14M▲ 13.6% | -31.74M▼ 8.9% | -42.51M▼ 33.9% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 146K | 158K | 7K | 20K | 16K | 6K | 121K |
| Effective Tax Rate % | -1.76% | -1.81% | -0.03% | -0.06% | -0.05% | -0.02% | -0.28% |
| Net Income | -8.46M▲ 0% | -8.88M▼ 4.9% | -27.27M▼ 207.0% | -33.76M▼ 23.8% | -29.16M▲ 13.6% | -31.75M▼ 8.9% | -42.63M▼ 34.3% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -4.94% | -207.04% | -23.8% | 13.64% | -8.89% | -34.26% |
| Net Income (Continuing) | -8.46M | -8.88M | -27.27M | -33.76M | -29.16M | -31.75M | -42.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.13▲ 0% | -0.22▼ 69.2% | -0.67▼ 204.5% | -0.53▲ 20.9% | -0.42▲ 20.8% | -0.45▼ 7.1% | -0.53▼ 17.8% |
| EPS Growth % | - | -69.23% | -204.55% | 20.9% | 20.75% | -7.14% | -17.78% |
| EPS (Basic) | -0.13 | -0.22 | -0.67 | -0.53 | -0.42 | -0.45 | -0.53 |
| Diluted Shares Outstanding | 67.62M | 40.43M | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
| Basic Shares Outstanding | 67.62M | 40.43M | 40.53M | 63.53M | 69.38M | 69.93M | 80.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
DRTS Balance Sheet
Alpha Tau Medical Ltd. (DRTS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 29.83M | 47.45M | 32.64M | 106.48M | 85.76M | 64.23M | 78.3M |
| Cash & Short-Term Investments | 28.13M | 46.02M | 31.32M | 104.53M | 81.79M | 59.6M | 76.9M |
| Cash Only | 1.83M | 15.6M | 23.24M | 5.84M | 12.66M | 13.72M | 15.98M |
| Short-Term Investments | 26.3M | 30.42M | 8.08M | 98.69M | 69.13M | 45.88M | 60.92M |
| Accounts Receivable | 141K | 477K | 480K | 32K | 19K | 332K | 36K |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 1.13M | 0 | -8.17M | 0 | -19K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | -187.3K | 576K | 8.79M | 1.13M | 3.5M | 3.25M | 0 |
| Total Non-Current Assets | 1.73M | 5.53M | 9.57M | 13.67M | 21.63M | 21.98M | 28.28M |
| Property, Plant & Equipment | 1.71M | 5.39M | 7.55M | 13.28M | 21.16M | 21.54M | 26.88M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 16K | 139K | 2.03M | 391K | 471K | 432K | 479K |
| Total Assets | 31.56M▲ 0% | 52.99M▲ 67.9% | 42.22M▼ 20.3% | 120.15M▲ 184.6% | 107.39M▼ 10.6% | 86.2M▼ 19.7% | 106.58M▲ 23.6% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 67.92% | -20.33% | 184.61% | -10.62% | -19.73% | 23.64% |
| Total Current Liabilities | 1.35M | 2.09M | 4.41M | 4.34M | 7.1M | 8.68M | 10.51M |
| Accounts Payable | 893K | 964K | 1.2M | 1.42M | 2.57M | 3.53M | 3.87M |
| Days Payables Outstanding | - | 4.09K | 565.84 | 530.54 | 872.06 | 1.17K | 1.15K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1.06M | 1.01M | 1.13M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 599K | 2.41M | 1.34M | -983K | 389K | 3.78M |
| Current Ratio | 22.11x | 22.73x | 7.41x | 24.55x | 12.07x | 7.40x | 7.45x |
| Quick Ratio | 21.27x | 22.73x | 9.26x | 24.55x | 12.08x | 7.40x | 7.45x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 30.4M | 59.33M | 72.59M | 10.15M | 15.81M | 14.86M | 18.97M |
| Long-Term Debt | 0 | 53.96M | 53.96M | 0 | 5.61M | 5.56M | 6.35M |
| Capital Lease Obligations | 0 | 0 | 0 | 4.52M | 6.6M | 5.96M | 6.24M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M |
| Other Non-Current Liabilities | 30.4M | 5.37M | 18.62M | 5.63M | 3.6M | 3.34M | 5.35M |
| Total Liabilities | 31.75M | 61.42M | 76.99M | 14.49M | 22.91M | 23.54M | 29.48M |
| Total Debt | 0 | 53.96M | 53.96M | 5.19M | 13.28M | 12.54M | 13.73M |
| Net Debt | -1.83M | 38.37M | 30.73M | -643K | 619K | -1.19M | -2.25M |
| Debt / Equity | - | - | - | 0.05x | 0.16x | 0.20x | 0.18x |
| Debt / EBITDA | - | - | - | - | 0.36x | - | - |
| Net Debt / EBITDA | - | - | - | - | 0.02x | - | - |
| Interest Coverage | - | -42.60x | -1.04x | -18.17x | 914.87x | -104.77x | -100.93x |
| Total Equity | -193K▲ 0% | -8.43M▼ 4267.4% | -34.78M▼ 312.6% | 105.66M▲ 403.8% | 84.47M▼ 20.0% | 62.67M▼ 25.8% | 77.1M▲ 23.0% |
| Equity Growth % | - | -4267.36% | -312.59% | 403.81% | -20.05% | -25.82% | 23.03% |
| Book Value per Share | -0.00 | -0.21 | -0.86 | 1.66 | 1.22 | 0.90 | 0.96 |
| Total Shareholders' Equity | -193K | -8.43M | -34.78M | 105.66M | 84.47M | 62.67M | 77.1M |
| Common Stock | 0 | 690 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -16.69M | -25.57M | -52.84M | -86.6M | -115.76M | -147.51M | -190.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -21K | -60.02K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRTS Cash Flow Statement
Alpha Tau Medical Ltd. (DRTS) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.91M | -7.25M | -11.81M | -23.88M | -17.96M | -19.78M | -26.68M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -4.93% | -62.9% | -102.16% | 24.8% | -10.16% | -34.87% |
| Net Income | -8.46M | -8.88M | -27.27M | -33.76M | -29.16M | -31.75M | -42.63M |
| Depreciation & Amortization | 66K | 86K | 776K | 979K | 1.07M | 1.1M | 1.23M |
| Stock-Based Compensation | 546K | 596K | 812K | 6.75M | 7.93M | 9.92M | 0 |
| Deferred Taxes | 994K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 12K | 50K | 13.29M | 2.46M | -293K | -219K | 12.42M |
| Working Capital Changes | -64K | 899K | 585K | -307K | 2.49M | 1.17M | 2.29M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 148K | 114K | 239K | 220K | 1.14M | 965K | 337K |
| Cash from Investing | -10.16M | -7.82M | 19.27M | -89.94M | 18.68M | 20.77M | -20.59M |
| Capital Expenditures | -1.29M | -3.77M | -2.93M | -904K | -6.4M | -2.24M | -6.08M |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 8.87K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -8.87K | -4.05M | 22.2M | -89.03M | 25.08M | -103K | 0 |
| Cash from Financing | 5.32M | 29.32M | 111K | 96.91M | 5.3M | 25K | 45.77M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 111K | 1000K | 49K | 25K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 73K | 0 | 0 | 93.54M | 5.25M | 0 | 0 |
| Net Change in Cash | -11.77M▲ 0% | 16.17M▲ 237.4% | 7.68M▼ 52.5% | -17.17M▼ 323.5% | 9.12M▲ 153.1% | 1.17M▼ 87.2% | -1M▼ 185.5% |
| Free Cash Flow | -8.2M▲ 0% | -11.02M▼ 34.3% | -14.74M▼ 33.8% | -24.78M▼ 68.1% | -24.36M▲ 1.7% | -22.02M▲ 9.6% | -32.76M▼ 48.7% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -34.32% | -33.77% | -68.15% | 1.71% | 9.6% | -48.75% |
| FCF per Share | -0.12 | -0.27 | -0.36 | -0.39 | -0.35 | -0.31 | -0.41 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.82x | 0.43x | 0.71x | 0.62x | 0.62x | 0.63x |
| Interest Paid | 0 | 0 | 0 | 0 | 52K | 321K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DRTS Key Ratios
Alpha Tau Medical Ltd. (DRTS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -95.27% | -30.67% | -43.16% | -61% |
| Return on Invested Capital (ROIC) | - | -49.68% | -79.9% | -47.74% | 28.15% | -36.88% | -46.53% |
| Debt / Equity | - | - | - | 0.05x | 0.16x | 0.20x | 0.18x |
| Interest Coverage | - | -42.60x | -1.04x | -18.17x | 914.87x | -104.77x | -100.93x |
| FCF Conversion | 0.82x | 0.82x | 0.43x | 0.71x | 0.62x | 0.62x | 0.63x |
DRTS Frequently Asked Questions
Alpha Tau Medical Ltd. (DRTS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alpha Tau Medical Ltd. (DRTS) grew revenue by 0.0% over the past year. Growth has been modest.
Alpha Tau Medical Ltd. (DRTS) reported a net loss of $42.6M for fiscal year 2025.
Dividend & Returns
Alpha Tau Medical Ltd. (DRTS) has a return on equity (ROE) of -61.0%. Negative ROE indicates the company is unprofitable.
Alpha Tau Medical Ltd. (DRTS) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More DRTS
Alpha Tau Medical Ltd. (DRTS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates